Exogems SA, a pioneering Swiss biotech startup developing innovative therapeutic exosomes derived from microfragmented adipose tissue, announcew the successful completion of a CHF 500K fundraising round from business angels. This significant investment will fuel the company’s mission to harness the potential of exosomes in treating inflammation, infection, and cancer.
